The company is developing an adoptive cell therapy where a patient's own immune cells (lymphocytes) are extracted from their tumor, expanded in a laboratory setting, and then re-infused to attack the cancer. A key aspect of their development process is a novel enhancement technique that infuses the TILs with healthy mitochondria to counteract a mechanism cancer cells use to disable T cells, thereby improving therapeutic potency.